Triple-negative breast cancer

Where the papers sit

18 papers from the last 6 months study triple-negative breast cancer directly · updated from PubMed 12 Oct 2026

• Tumor Microenvironment and Treatment Response

  Treatment response is being tied to the tumor microenvironment, with Schwann cells associated with EMT and immune suppression and HER2-low tumors showing poorer immunotherapy response. Neoadjuvant chemotherapy and postmastectomy radiation remain the clinical backbone, assessed through pathologic response and real-world outcomes. Preclinical approaches aim to restore vascular integrity with P188 or trigger STING with ROS-generating nanomedicine. TFAP2B and FOXC1 states, plus whole-genome signatures, point toward molecularly selected treatment.

  8 papers · 44.4%

• Natural Products and RAS-ERK Signaling

  Natural-product discovery is generating experimental leads against triple-negative breast cancer rather than established treatments. Sesquiterpenoid glucosides and isoprenylated phenolics suppress growth in cell-based assays, including MDA-MB-231 models. The reported activity is linked to RAS-ERK signaling and supported by structural characterization and 50% inhibitory concentration measurements. Translation beyond in vitro efficacy and identification of active clinical candidates remain open.

  2 papers · 11.1%

• HSP90 and Biomarker-Guided Therapy

  Biomarker-guided testing is moving triple-negative breast cancer drug discovery toward patient-derived organoids and molecularly selected responses. The set highlights HSP90 as a target, with bakuchiol supported by in silico, in vitro, and synergy studies. Organoid studies assess responses to therapies including cisplatin and veliparib. Clinical validation, predictive biomarkers, and the durability of HSP90 inhibition remain unresolved.

  2 papers · 11.1%

• Others — Detection, Access, and Outcomes

  Infrared spectroscopy and near-infrared nanomedicine are being explored for diagnosis, recurrence detection, and image-guided treatment. Population studies add five-year survival estimates and examine geographic access to clinical trials. Preclinical work also links phototherapy, calorie restriction, and exercise to tumor control, with conflicting effects. The cluster has no single biological or clinical direction beyond measuring and treating triple-negative breast cancer.

  6 papers · 33.3%